Pediyatrik Popülasyonda COVID-19 Pandemisi

Öz

Bugüne kadar hem hayvan hem de insanlarda enfeksiyon oluşturduğu bilinen koronavirus ailesine, 2019 yılı sonlarında, kümelenmiş atipik pnömoni vakalarında tanımlanan yeni tip bir koronavirus eklenmiştir. Pandemi ilanına sebep olan bu virus özellikle ileri yaş ve komorbid hastalığı olan erişkin yaş grubunda etkili olmuştur. Çocukluk çağında çoğunlukla kendini hafif hastalık olarak gösteren bu etken nadir de olsa kritik hastalık tablosu meydana getirmektedir. Ortaya çıktığı andan itibaren destek tedavi uygulamalarının yanında çeşitli antiviral tedaviler denenmiştir. Ağırlıklı olarak erişkin yaş grubunda uygulanan bu tedavilerin kısmen etkili olduğu bildirilse de virusa spesifik tedavi seçeneği henüz mevcut değildir. İlaç ve aşı geliştirme çalışmaları bir umut ışığı oluştursa da enfeksiyondan kaçınabilmenin şimdilik tek yolu korunma önlemlerine uymaktan geçer.

Anahtar Kelimeler

• SARS-CoV-2
• çocuk
• COVID-19 hastalığı

COVID-19 Pandemia in Pediatric Population

Öz

A new type of coronavirus, identified in clustered atypical pneumonia cases, was added to the family of coronavirus known to cause infection in both animals and humans to date. This virus, which caused the announcement of pandemic, was especially effective in the adult age group with advanced age and comorbid disease. This factor, which generally manifests itself as a mild disease in childhood, rarely creates a critical disease picture. Various antiviral therapies have been tried as well as supportive treatments since its emergence. Although it is reported that these treatments, which are mostly administered in the adult age group, are partially effective, virusspecific treatment options are not yet available. Although drug and vaccine development efforts create a glimmer of hope, the only way to avoid infection is to follow the protection measures for now.

Anahtar Kelimeler

• SARS-CoV-2
• COVID-19 disease
• child

Kaynakça

1. 1. Beaudette FR, Hudson CB. Cultivation of the virus of infectious bronchitis. J Am Vet Med Assoc 1937;90:51-8.
2. 2. Ogimi C, Kim YJ, Martin ET, Huh HJ, Chiu CH, Englund JA. What’s new with the old coronaviruses? J Pediatr Infect Dis Soc 2020;9(2):210- 17. doi:10.1093/jpids/piaa037
3. 3. Englund J, Kim Y, McIntosh K. Human coronaviruses, including Middle East respiratory syndrome coronavirus. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases [Internet]. 8th ed. Philadelphia, PA: Elsevier; 2019. [1 online resource (xxvi, 2696)]. Available at: Clinical Key https://www.clinicalkey.com/dura/browse/ bookChapter/3-s2.0- C20141033200. AccessedFebruary 10, 2020.
4. 4. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74.
5. 5. World Health Organization. Director-General’s remarks at the media briefing on 2019- nCoV on 11 February 2020. https://www. who.int/dg/speeches/detail/who-director-general- s-remarks-atthe- media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on May 28, 2020.)
6. 6. Chan JF, Yuan S, Kok KH, To KK, Chu H et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514-23. doi: 10.1093/infdis/jiaa077
7. 7. World Health Organization (WHO). WHO Director-General’s opening remarks at the media briefing on COVID-19 11 March 2020. Available from: https://www.who.int/dg/speeches/detail/ who-director-general-s-opening-remarks-at-the- media-briefingon- covid-19---11-march-2020 (Accessed on May 28, 2020.)
8. 8. World Health Organization (WHO). Emergencies, Diseases, Coronavirus disease 2019. Available from https://www.who.int/emergencies/ diseases/novel-coronavirus-2019. (Accessed on May 28, 2020.)

9. 9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270.
10. 10. Shereen MA, Khan S, Kazmi A, et al. COVID-19 Infection: Origin, Transmission, and Characteristics of Human Coronaviruses. J Adv Res 2020;24:91.
11. 11. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv 2020. https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1 (Accessed on February 12, 2020).
12. 12. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14(2):185-192. doi:10.1007/s11684-020-0754-0
13. 13. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426(6965):450-454. doi:10.1038/nature02145
14. 14. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020;215:108427. doi:10.1016/j. clim.2020.108427
15. 15. Bautista-Vargas M, Bonilla-Abadía F, Cañas CA. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19 [published online ahead of print, 2020 Jun 9]. J Thromb Thrombolysis 2020;1-5. doi:10.1007/s11239-020-02172-x
16. 16. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0
17. 17. Palmeira P, Barbuto JAM, Silva CAA, Carneiro-Sampaio M. Why is SARS-CoV-2 infection milder among children? Clinics (Sao Paulo) 2020;75:e1947. doi:10.6061/clinics/2020/e1947
18. 18. Cao Q et al., SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics, Journal of the Formosan Medical Association, https://doi.org/10.1016/j.jfma.2020.02.009
19. 19. World Health Organization (2020). Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Scientific brief. 29 March 2020 [online]. Available from https://www.who.int/news-room/commentaries/ detail/modes-oftransmission-of-virus-causing-covid-19- implications-for-ipc-precaution- recommendations [accessed 29 June 2020].
20. 20. D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management [published online ahead of print, 2020 Apr 8]. Clin Gastroenterol Hepatol. 2020;S1542- 3565(20)30481-X. doi:10.1016/j.cgh.2020.04.001
21. 21. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARSCoV- 2: maternal coronavirus infections and pregnancy outcomes. Archives of Pathology and Laboratory Medicine 2020. doi: 10.5858/arpa.2020-0901-SA.
22. 22. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382:1199.
23. 23. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med 2020;172(9):577-82. doi:10.7326/M20-0504
24. 24. Shin KS, Park HS, Lee J, Lee JK. Environmental surface testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during prolonged isolation of an asymptomatic carrier [published online ahead of print, 2020 Jun 16]. Infect Control Hosp Epidemiol. 2020;1-9. doi:10.1017/ice.2020.300
25. 25. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104(3):246-251. doi:10.1016/j. jhin.2020.01.022.
26. 26. Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: A narrative review [published online ahead of print, 2020 Jun 3]. Ann Intern Med. 2020;M20-3012. doi:10.7326/M20-3012
27. 27. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088.
28. 28. United States Centers for Disease Control and Prevention. Cases in the US. Available at: https://www.cdc.gov/coronavirus/2019-ncov/ cases-updates/cases-in-us.html (Accessed on June 17, 2020).
29. 29. CDC COVID-19 Response Team. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422.
30. 30. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among Black patients and White patients with Covid-19. N Engl J Med 2020.
31. 31. Parri N, Lenge M, Buonsenso D, Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in Pediatric Emergency Departments in Italy [published online ahead of print, 2020 May 1]. N Engl J Med 2020;NEJMc2007617. doi:10.1056/NEJMc2007617
32. 32. Tong JY, Wong A, Zhu D, et al. The prevalence of olfactory and gustatory Dysfunction in COVID-19 Patients: A systematic review and meta-analysis. Otolaryngol Head Neck Surg 2020;163(1):3-11. doi:10.1177/0194599820926473
33. 33. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China [published online ahead of print, 2020 Mar 16]. Pediatrics 2020;e20200702. doi:10.1542/peds.2020-0702
34. 34. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020;183(1):71-7. doi:10.1111/bjd.19163
35. 35. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol 2020;S0190-9622(20)30558-2. doi:10.1016/j. jaad.2020.04.018
36. 36. Madigan LM, Micheletti RG, Shinkai K. How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic. JAMA Dermatol 2020;10.1001/jamadermatol. 2020.1438. doi:10.1001/jamadermatol.2020.1438
37. 37. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17:259.
38. 38. World Health Organization, Newsroom, Commentaries, Detail, Scientific Brief: Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Available from: https://www.who.int/news- room/commentaries/ detail/multisystem-inflammatory-syndrome-in-children-andadolescents- with-covid-19 (Accessed on June 24, 2020).
39. 39. T. C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, COVID-19, Yeni Koronavirus Hastalığı, Rehberler, Çocuk Hasta Yönetimi ve Tedavisi, 3 Haziran 2020. Available from https://covid19bilgi. saglik.gov.tr/depo/rehberler/covid-19-rehberi/COVID-19_ REHBERI_COCUK_HASTA_YONETIMI_VE_TEDAVI.pdf. Accessed on June 24, 2020.
40. 40. Lieberman JA, Pepper G, Naccache SN, et al. Comparison of commercially available and laboratory developed assays for in vitro detection of SARS-CoV-2 in clinical Laboratories. J Clin Microbiol 2020;JCM.00821-20. doi:10.1128/JCM.00821-20
41. 41. Long DR, Gombar S, Hogan CA, et al. Occurrence and timing of subsequent SARS-CoV-2 RT-PCR positivity among initially negative patients. Clin Infect Dis 2020;ciaa722. doi:10.1093/cid/ciaa722
42. 42. Cheng MP, Yansouni CP, Basta NE, et al. Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A narrative review. Ann Intern Med 2020;M20-2854. doi:10.7326/M20-2854
43. 43. US Food and Drug Administration Statement: Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of theVirus that Causes COVID-19 in Patients. https://www.fda.gov/news-events/press- announcements/ coronavirus-covid-19-update-fda-authorizes-first-antigen-testhelp- rapid- detection-virus-causes (Accessed on June 29, 2020).
44. 44. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection https://www.acr.org/Advocacy-and- Economics/ACR-Position- Statements/Recommendations-for-Chest-Radiography-and-CTfor- Suspected-COVID19-Infection (Accessed on June 26, 2020).
45. 45. Bao C, Liu X, Zhang H, et al. Coronavirus Disease 2019 (COVID-19) CT findings: A systematic review and meta-analysis. J Am Coll Radiol 2020;17:701.
46. 46. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York city. N Engl J Med 2020;382:2372.
47. 47. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(7):1021-28. doi:10.1515/cclm-2020-0369
48. 48. US FDA. Remdesivir letter of EUA. https://www.fda.gov/ media/137564/download (Accessed on June 29, 2020).
49. 49. US FDA. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. June 15, 2020. https://www.fda.gov/news-events/press-announcements/ coronavirus-covid-19-update-fda-revokes-emergency-useauthorization- chloroquine-and (Accessed on June 29, 2020).
50. 50. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med 2020 Feb 25;:]. Lancet Respir Med 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-X
51. 51. Tezer H, Bedir Demirdağ T. Novel coronavirus Disease (COVID-19) in children. Turk J Med Sci 2020;50:592-603.
52. 52. T. C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, Koronavirus, COVID-19 Yeni Koronavirus Hastalığı, COVID-19 Rehberi, Genel Bilgiler, Epidemiyoloji ve Tanı, Ankara, 29 Haziran 2020. Available from https://covid19bilgi.saglik.gov.tr/depo/rehberler/covid-19- rehberi/COVID-19_REHBERI_GENEL_BILGILER_EPIDEMIYOLOJI_ VE_TANI.pdf. Accessed on June 29, 2020.
53. 53. World Health Organization, Health Topics, Coronavirus disease (COVID-19), Research and Guidance, Global Research, Update on WHO Solidarity Trial-Accelerating a safe anf effective COVID-19 vaccine, Draft landscape of COVID-19 candidate vaccines. Available from https://www.who.int/who-documents-detail/draftlandscape- of-covid-19-candidate-vaccines. Accessed on 29 June 2020.